Lopend onderzoek en publicaties dermatologie

Lopend onderzoek

• ADHope
• Allo-APZ2-CVU-III
• BioDay registry
• Broswitch
• CDX0159-13 / EMBARQ
• INCB 18424-326 / TRUE AD
• M16-047
• M19-044
• OBS17721
• ROCKET-ASCEND
• STOP-V1

Publicaties

• Real-world Cost per Responder Among Different Classes of Biologics for the Treatment of Psoriasis (https://pubmed.ncbi.nlm.nih.gov/40534202/) Linda T H Godding, Marieke M B Seyger, Albert Duvetorp, Marisol E Otero, Paul M Ossenkoppele, Annet M Oostveen, M Birgitte Visch, Ella A M Van der Voort, John E M Körver, Lizelotte J M T Weppner-Parren, Maartje A M Berends, W Peter Arnold, Sharon R P Dodemont, Astrid L A Kuijpers, Johannes M Mommers, Femke M Homan, Antoni H Gostynski, Berit Velstra, Marloes M Kleinpenning, Martijn B A Van Doorn, Romy R M C Keijsers, Else N Kop, Inge M Haeck, Judith H J Hendricksen-Roelofzen, Douwe Vellinga, Elke M G J De Jong, Juul M P A Van den Reek. Acta Derm Venereol 2025 Jun 18:105:adv42767. doi: 10.2340/actadv.v105.42767.PMID: 40534202 PMCID: PMC12186437 DOI: 10.2340/actadv.v105.42767
   
• Impairment in work and activities of daily life in patients with psoriasis: results of the prospective BioCAPTURE registry. https://pubmed.ncbi.nlm.nih.gov/38263716/ van Hal TW, van den Reek JMPA, Wenink MH, Otero ME, Ossenkoppele PM, Njoo MD, Oostveen A, Peters B, Tjioe M, Kop EN, Körver JEM, Dodemont SRP, Kleinpenning MM, Berends MAM, Veldkamp WR, van Doorn MBA, Mommers JM, Lindhout RJ, Kuijpers ALA, van Lümig PP, de Jonge CEJ, Tupker RA, Hendricksen J, Keijsers RR, van den Hoogen FHJ, Vriezekolk JE, de Jong EMGJ. J Dermatolog Treat. 2024 Dec;35(1):2304025. doi: 10.1080/09546634.2024.2304025. Epub 2024 Jan 23. PMID: 38263716.
   
• Switching to Interleukin-23 Inhibitors After Ineffectiveness of Ustekinumab: Evaluating Real-World Outcomes in Psoriasis Treatment. https://pubmed.ncbi.nlm.nih.gov/38802618/ Thomas SE, Seyger MMB, Mangnus JE, Otero ME, Gostynski AH, Njoo MD, Ossenkoppele PM, Haeck IM, Hendricksen-Roelofzen JHJ, Körver JEM, Dodemont SRP, Tupker RA, Berends MAM, Weppner-Parren LMJT, Keijsers RRMC, Oostveen AM, Peters B, Mommers R, van Doorn MBA, Tjioe M, Veldkamp WR, Kuijpers ALA, Kleinpenning MM, de Jong EMGJ, van den Reek JMPA. Am J Clin Dermatol. 2024 Jul;25(4):685-688. doi: 10.1007/s40257-024-00868-x. Epub 2024 May 27. PMID: 38802618.
   
• Multi-treatment resistance to biological treatment in patients with psoriasis: Definitions and implications. https://pubmed.ncbi.nlm.nih.gov/38818854/ Henckens NFT, Thomas SE, van den Reek JMPA, de Jong EMGJ; BioCAPTURE Network.  J Eur Acad Dermatol Venereol. 2025 Feb;39(2):e110-e113. doi: 10.1111/jdv.20133. Epub 2024 May 31. PMID: 38818854.
   
• Psoriasis healthcare during the COVID-19 pandemic: a survey among psoriasis patients (PsoCovidCare). https://pubmed.ncbi.nlm.nih.gov/38897615/ Wortman CD, Godding LTH, Yin Q, Kwee KV, Visch MB, de Jong EMGJ, van den Reek JMPA, Tjioe M. J Dermatolog Treat. 2024 Dec;35(1):2369616. doi: 10.1080/09546634.2024.2369616. Epub 2024 Jun 19. PMID: 38897615.

• Real-world durability of effectiveness through 24 months of anti-interleukin-17A biologics and other approved biologics in treating patients with moderate-to-severe psoriasis in the Psoriasis Study of Health Outcomes https://academic.oup.com/bjd/article/191/Supplement_3/ljae360.094/7916126 Milan Tjioe, Antonio Costanzo, Jose Manuel Carrascosa, H. Jorn Bovenschen, Julia-Tatjana Maul, Niek de Hoog, Georgia Martimianaki, Anastasia Lampropoulou, Robert McKenzie, Andreas Pinter, British Journal of Dermatology, Volume 191, Issue Supplement_3, December 2024, ljae360.094, https://doi.org/10.1093/bjd/ljae360.094

• Real-world drug survival of Brodalumab, in patients with psoriasis switched from Ixekizumab: results of a single centre retrospective study (BroSwitch) (https://onlinelibrary.wiley.com/doi/full/10.1002/jvc2.173). Bethlem JC, Janssens JAHM, Tjioe M. JEADV Clin Pract. 2023; 2: 510–517. doi: 10.1002/jvc2.173
   
• Understanding comorbidities and concomitant medication patterns in patients with moderate- to-severe plaque psoriasis in the real-world Psoriasis Study of Health Outcomes (PSoHO) (https://www.jaad.org/article/S0190-9622(23)02336-8/abstract). Puig L, Schäkel K, Reich A, Zaheri S, Tjioe M, Brnabic A, de Hoog N, Reed C, Schuster C, Riedl E. doi: 10.1016/j.jaad.2023.07.979
   
• The growing importance of ultrasonography in cosmetic dermatology: An update after the 23rd IMCAS Annual World Congress (2022) (https://pubmed.ncbi.nlm.nih.gov/36374262/). Haykal D, Cartier H, Benzaquen M, Damiani G, Habib SM. J Cosmet Dermatol 2023 Jan;22(1):222-225. doi: 10.1111/jocd.15503
   
• Prevalence, risk and severity of SARS-CoV-2 infections in psoriasis patients receiving conventional systemic, biologic or topical treatment during the COVID-19 pandemic: a cross-sectional cohort study (PsoCOVID). (https://pubmed.ncbi.nlm.nih.gov/36545844/). Kwee KV, Murk JL, Yin Q, Visch MB, Davidson L, de Jong EMGJ, van den Reek JMPA, Tjioe M. J Dermatolog Treat. 2023 Jan;34(1):2161297. doi: 10.1080/09546634.2022.2161297. PMID: 36545844
   
• Paraneoplastische systemische sclerodermie op basis van een recidief melanoom. (https://nvdv.nl/storage/app/media/uploaded-files/Paraneoplastische%20systemische%20sclerodermie%20op%20basis%20van%20een%20%20recidief%20melanoom_Yin.pdf), Q. Yin, E.A.M. van der Voort. Nederlands Tijdschrift voor Dermatologie en Venereologie, jaargang 31, nummer 9, oktober 2021